During a departmental grand rounds, a pulmonologist presents a proposal for a new prospective clinical trial. The study aims to evaluate whether a novel inhaler formulation reduces the frequency of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) compared to standard therapy. Initial calculations indicate that subjects are required to achieve power at an . However, the trial's recruitment period is strictly limited, and realistic estimates suggest a maximum enrollment of only subjects. The principal investigator asks the research committee for strategies to maintain the study's statistical power despite the smaller-than-planned sample size.
Which of the following design modifications is most likely to accomplish this objective?
- ADecreasing the acceptable Type I error rate () for the primary analysis from to
- BBroadening the study population to include patients with mild disease to improve external validity
- Limiting participation to patients with a history of frequent exacerbations to increase the expected absolute effect sizeAnswer
- DSelecting a primary outcome measure that inherently possesses greater inter-subject measurement variance
- EAdjusting the study protocol to decrease the acceptable probability of a Type II error () from to